Andrew is a transfer pricing partner with PwC’s Toronto office. He has been with the firm for more than 30 years, and has been a partner since 1997. He began his career in transfer pricing in PwC’s New York office in 1994, assisting companies in complying with the first U.S. contemporaneous documentation requirements and now specialises in transfer pricing controversy and dispute resolution.
His extensive cross-border experience includes prospective studies for planning purposes, income tax audit defence, contemporaneous documentation engagements, Competent Authority assistance and Advance Pricing Agreements (APAs). He has helped clients in obtaining unilateral and bilateral APAs in a variety of industries, including mining, manufacturing, automotive, entertainment, retail and software, in countries including the United States, United Kingdom, Germany, Australia and, most recently, India.
Andrew is a CPA and a Chartered Business Valuator (CBV). As a CBV, he brings a wealth of valuation experience to international restructuring, cost sharing and intellectual property migration assignments.
The Euromoney Guide to the World’s Leading Transfer Pricing Advisers has featured Andrew since 2003, and in 2011 he was voted one of the “Best of the Best,” a ranking of the top five advisers in Canada. He is also recognised in International Tax Review’s Tax Controversy Leaders.
As a leader in the field, Andrew speaks regularly on transfer pricing and business valuation topics for a number of professional organisations. He has also written articles for CA Magazine, the Canadian Tax Foundation, the Journal of Business Valuation and Tax Planning International Review. He co-authored “The Dilemma of GlaxoSmithKline: Unreasonable in the Circumstances?” and “Transfer Pricing: A Critique of the CRA’s Position on Range Issues,” both published by the Canadian Tax Foundation.